Icon

ZELBORAF (nda202429)- (240MG)

VEMURAFENIB HOFFMANN LA ROCHE
240MG
No No
2032-Jun-06 2016-Aug-17
2018-Aug-17 None
None No
ZELBORAF® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ZELBORAF® is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.
0 0 0
Total Other Developers None
Drugs with Suitability No
240MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.